Introduction
============

Atherothrombosis has been proposed as a composite disease that includes myocardial infarction, non-cardioembolic stroke, and peripheral artery disease. This is reasonable because each of the conditions is based on systemic atherosclerosis. Additionally, peripheral artery disease can be highly complicated with stroke. In the REACH Registry, 8.5% of patients with prior stroke and transient ischemic attack had peripheral artery disease and 23.0% of patients with peripheral artery disease had stroke and transient ischemic attack^[@bib1])^. Additionally, 2.6% of patients with peripheral artery disease developed nonfatal stroke and 8.8% died from stroke or myocardial infarction during a 2-year follow-up period^[@bib2])^.

Pulse wave velocity (PWV) reflects segmental arterial elasticity. Although carotid-femoral PWV is currently the gold standard measurement method, brachial-ankle PWV (baPWV) is a more convenient and widely available method. It is well correlated with carotid-femoral PWV and indicates central arterial stiffness^[@bib3],\ [@bib4])^. BaPWV is associated with subclinical stage of atherosclerosis and is an independent predictor of future cardiovascular events^[@bib5],\ [@bib6])^. Recently, the ankle brachial index (ABI) and baPWV were reported as predictive factors of stroke outcome^[@bib7]--[@bib10])^. Additionally, there is an inter-influence between atherosis and sclerosis, with ABI indicating arterial atherosis^[@bib11])^ and baPWV indicating sclerosis^[@bib12],\ [@bib13])^. However, it has been reported that the accuracy of baPWV in evaluating pathophysiological conditions related to atherosclerosis diminishes when ABI is low^[@bib14],\ [@bib15])^. Therefore, with regard to atherosclerosis pathophysiology, ABI and baPWV are related. Previous studies have not considered the relation between ABI and baPWV in the evaluation of their influence on stroke outcomes.

Aim
===

In the present study, we aimed to evaluate the ability of ABI and baPWV to predict stroke outcome in patients with first-ever non-cardioembolic stroke. We hypothesized that ABI and baPWV may affect modifiers of each other with their influence on stroke outcome. Additionally, the influence of baPWV on stroke outcome may differ between patients with ABI \< 0.9 and those with ABI ≥ 0.9.

Methods
=======

Study Design and Participants
-----------------------------

A total of 2413 patients with acute ischemic stroke, without transient ischemic attack, and who were admitted to our Brain Attack Center between January 2011 and December 2013 were considered for inclusion in this study. Among these patients, 597 with cardioembolic stroke, 730 with a prior stroke history, 76 admitted later than 7 days after stroke onset, 92 with tissue plasminogen activator treatment, 142 who received endovascular therapy, 62 who underwent surgical operation, and 546 with premorbid mRS ≥ 2 were excluded from this study. In addition, there were 105 patients without available ABI and baPWV data and 53 patients without 3-month modified Rankin scale (mRS) data. Finally, 861 patients with first-ever acute non-cardioembolic stroke (285 female patients; mean age, 70.2 ± 11.6 years) were available for evaluation in this study (**[Fig. 1](#F1){ref-type="fig"}**). This study was approved by the institutional review board of Brain Attack Center Ota Memorial Hospital (No. 133) and was performed according to the Ethical Guidelines for Medical and Health Research Involving Human Subject^[@bib16])^ based on the Helsinki Declaration of 1964. Because this was a retrospective study, we did not obtain the patient\'s consent.
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Diagnosis of Stroke and Date Collection
---------------------------------------

The final diagnosis of the stroke subtype was made before discharge using echocardiography, brain computed tomography, magnetic resonance imaging, magnetic resonance angiography, and carotid ultrasonography according to the Trial of Org 10172 in Acute Stroke Treatment classification^[@bib17])^. Physicians collected detailed data from all patients, including baseline characteristics \[age, sex, body mass index (BMI), and drinking and smoking habits\], vascular risk factors (hypertension, dyslipidemia, and diabetes mellitus), use of antithrombotic agent prior to the stroke incidence, and neurologic deficits at admission using the National Institutes of Health stroke scale (NIHSS) score. Hypertension was defined as the use of anti-hypertensive medications prior to admission or a confirmed blood pressure ≥ 140/90 mmHg 2 weeks after stroke onset. Diabetes mellitus was defined as an HbA1c value of ≥ 6.5%, fasting blood sugar level ≥ 126 mg/dL, or the use of anti-diabetic medications. Dyslipidemia was defined as a total cholesterol level ≥ 220 mg/dL, low-density lipoprotein cholesterol level ≥ 140 mg/dL, high-density lipoprotein cholesterol level \< 40 mg/dL, triglyceride level ≥ 150 mg/dL at admission, or the use of anti-dyslipidemia medications. mRS scores were evaluated 3 months after onset, and patients were categorized into good outcome (mRS score, 0 and 1) or poor outcome (mRS score, 2--6) groups.

Measurements of ABI and baPWV
-----------------------------

ABI and baPWV were evaluated within 5 days of hospitalization. Brachial-ankle arterial blood pressures were simultaneously measured using a noninvasive automatic device (model BP-203RPE-III; Nihon Colin, Tokyo, Japan) after a 5-min rest in the supine position. ABI was defined as the ratio of systolic blood pressure in the ankle (dorsalis pedis and posterior tibial arteries) and the higher side of the two brachial arteries. The laterality, which showed a lower ABI, was used for evaluation. baPWV on each side was calculated as the transmission distance divided by the transmission time. The transmission time between the right arm and both ankles was calculated using the waveform. The transmission distance between the right brachium and ankle was automatically calculated according to the height of the patient. baPWV was evaluated on the higher side.

Statistical Analysis
--------------------

Data are expressed as mean ± standard deviation (SD) or median (25th and 75th percentiles) for continuous variables and as frequency and percentage for discrete variables. The statistical significance of intergroup differences was assessed using the analysis of variance, Kruskal--Wallis test, or *χ*^2^ test, as appropriate. Univariate and multivariate logistic regression analyses were performed to evaluate association of factors with poor outcome, and the odds ratios and 95% confidence intervals were calculated. The receiver operation characteristic curve was used to determine a cut-off baPWV for predicting poor outcome. In multivariate logistic regression analysis, factors that showed intergroup difference in evaluation with *p*-values \< 0.2 in the univariate analysis were used for adjustment. Statistical significance was set at a p value \< 0.05. All statistical analyses were performed using JMP 12.0.1 statistical software (SAS Institute Inc., Cary, NC, USA).

Results
=======

ABI was less than 0.9 in 72 (8.4%) patients. The mean baPWV was 2059 ± 491 cm/s. On plotting the values of ABI and baPWV, there were linear associations between these values, separately for low (\< 0.9) and high ABI (≥ 0.9) (**[Fig. 2](#F2){ref-type="fig"}**). Poor outcome 3 months after onset was noted in 254 (29.5%) patients. ABI \< 0.9 and baPWV were associated with poor outcome in the univariate analysis (*p* \< 0.001 and *p* \< 0.001, respectively). The cut-off of baPWV for predicting poor outcome was 1870 cm/s.
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Patients were categorized into four groups by combination of ABI (ABI \< 0.9 or ≥ 0.9) and baPWV (baPWV \> 1870 cm/s or ≤ 1870 cm/s). We classified patients with ABI ≥ 0.9 and baPWV ≤ 1870 cm/s as group 1 (*n* = 316), those with ABI ≥ 0.9 and baPWV \> 1870 cm/s as group 2 (*n* = 473), those with ABI \< 0.9 and baPWV ≤ 1870 cm/s as group 3 (*n* = 21), and those with ABI \< 0.9 and baPWV \> 1870 cm/s as group 4 (*n* = 51). Baseline characteristics of the patients are presented in **[Table 1](#T1){ref-type="table"}**. Age, BMI, ischemic stroke subtype, NIHSS score on admission, smoking, hypertension, diabetes mellitus, and usage of antithrombotic agent were significantly different among four groups. The NIHSS score was higher in group 4 than in group 1 (*P* = 0.002). Proportions of poor outcome (3 months mRS, 2--6) were significantly higher in group 3 and 4 (*p* \< 0.001, **[Fig. 3](#F3){ref-type="fig"}**). With multivariate logistic regression models adjusted with these factors, group 2 showed slightly high odds ratio compared with group 1, although there was no statistical significance. Group 3 and 4 were significantly associated with poor outcome (**[Table 2](#T2){ref-type="table"}**).

###### Characteristics among the patients categorized with the ABI and baPWV

                                  Group 1       Group 2      Group 3       Group 4      *P*-value
  ------------------------------- ------------- ------------ ------------- ------------ -----------
  Age, years                      63.2 ± 11.8   74.1 ± 9.1   72.5 ± 14.4   76.9 ± 8.7   \< 0.001
  Female, *n* (%)                 101 (32.0)    160 (33.8)   9 (42.9)      15 (29.4)    0.679
  BMI                             23.9 ± 3.6    23.2 ± 3.4   23.3 ± 2.8    23.0 ± 3.7   0.019
  Ischemic stroke                                                                       
      Subtype                                                                           \< 0.001
          LAA, *n* (%)            76 (24.1)     127 (26.9)   11 (52.3)     27 (53.0)    
          SVO, *n* (%)            129 (40.8)    166 (35.1)   4 (19.1)      10 (19.6)    
          Other, *n* (%)          24 (7.6)      19 (4.0)     2 (9.5)       2 (3.9)      
      Undetermined, *n* (%)       87 (27.5)     161 (34.0)   4 (19.1)      12 (23.5)    
  NIHSS score on admission        2 \[1--3\]    2 \[1--4\]   3 \[1--4\]    4 \[2--5\]   0.002
  (median \[IQR\])                                                                      
  Drinking, *n* (%)               143 (45.4)    190 (40.6)   6 (28.6)      20 (39.2)    0.310
  Smoking, *n* (%)                177 (56.0)    178 (38.4)   11 (52.4)     23 (45.1)    \< 0.001
  Hypertension, *n* (%)           211 (69.6)    374 (81.1)   16 (76.2)     47 (92.2)    \< 0.001
  Dyslipidemia, *n* (%)           189 (60.4)    272 (58.0)   12 (57.1)     28 (56.0)    0.889
  Diabetes mellitus, *n* (%)      99 (31.5)     176 (37.5)   11 (52.4)     27 (52.9)    0.008
  Antithrombotic agent, *n* (%)   23 (7.3)      60 (12.7)    5 (23.8)      13 (25.5)    \< 0.001

ABI, ankle brachial index; baPWV, brachial-ankle pulse wave velocity; LAA, large artery atherosclerosis; SVO, small vessel occlusion; NIHSS, National Institutes of Health stroke scale; IQR, interquartile raange; 3M mRS, modified Rankin scale 3-month after onset
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###### Odds ratio for poor outcome of groups categorized with ABI and baPWV

                  ABI ≥ 0.9           ABI \< 0.9
  --------------- ------------------- --------------------
  baPWV ≤ 1870    Group 1             Group 3
                  *N* = 316           *N* = 21
                  1.0 (reference)     5.19 (1.85--15.14)
  baPWV \> 1870   Group 2             Group 4
                  *N* = 473           *N* = 51
                  1.46 (0.95--2.27)   3.37 (1.63--7.08)

Odds ratio (95% confidence intervals) was calculated with multivariate logistic regression analysis adjusted with age, body mass index, large artery atherosclerosis, National Institute of Health stroke scale on admission, smoking, hypertension, diabetes mellitus and antithrombotic agent, which associated with poor outcome.

ABI, ankle brachial index; baPWV, brachial-ankle pulse wave velocity.

Discussion
==========

In our study, among patients with first-ever noncardioembolic stroke, ABI \< 0.9 and baPWV was associated with the outcome 3 months after stroke onset. The outcome 3 months after stroke onset was poorer in patients with ABI \< 0.9 than in those with ABI ≥ 0.9. Among patients with ABI ≥ 0.9, baPWV \> 1870 cm/s had some prognostic value of poor outcome in comparison with patients with baPWV ≤ 1870 cm/s.

It has been reported that a low ABI of \< 0.9 has a prognostic value for mortality and incidences of coronary artery disease and stroke in the general population^[@bib18],\ [@bib19])^. In our study, 68.1% of the patients with a low ABI showed poor outcome 3 months after the events. A low ABI showed high predictivity for poor outcome 3 months after the events. Kim *et al.* reported that in patients with acute first-ever stroke, ABI \< 0.9 was a predictive factor for mRS 0--2 3 months after stroke onset^[@bib7])^. A previous study reported that the mortality rate of patients with ischemic stroke increases when peripheral artery disease is also present^[@bib20])^. Some studies showed an association between ABI \< 0.9 and an increase in mortality or recurrence of stroke in patients with acute stroke; therefore, poor outcome at 3 months may result from high mortality or recurrence of stroke^[@bib18],\ [@bib21]--[@bib23])^. In our study, the mortality rate was 4.3% in patients with low ABI and was 1.6% in patients with high ABI. Additionally, the stroke severity at admission was higher in patients with low ABI than in patients with high ABI. Therefore, it may have an influence on poor outcome.

Peripheral artery disease is present in 10.1% patients with cerebrovascular disease^[@bib24])^. In the present study, ABI \< 0.9 was noted in 8.4% of patients. A recent study showed that 20.1% of patients with acute ischemic stroke or transient ischemic attack were diagnosed with peripheral artery disease on computed tomography angiography, and the proportion of patients with a low ABI was 12.2%^[@bib25])^. The criterion of ABI \< 0.9 may underestimate the presence of peripheral artery disease, although it is widely used as a surrogate marker for peripheral artery disease. In this study, we did not perform any additional evaluation for peripheral artery disease. Therefore, there may be a higher proportion of patients with peripheral artery disease than those detected with a low ABI.

The findings of our study suggest that a high baPWV is a weak predictive factor for poor outcome when ABI is ≥ 0.9. Our scatter plot of ABI and baPWV and their regression lines suggested that the accuracy of baPWV may diminish when ABI is \< 0.9. Our results are supported by the findings of a previous study that reported associations of mortality with ABI and baPWV in patients undergoing dialysis^[@bib26])^. In this previous study, a high baPWV predicted mortality only in patients with ABI ≥ 0.9. Kim *et al.* reported an association between baPWV and the long-term outcome of acute first-ever stroke without consideration of ABI^[@bib8])^. They showed that patients with the highest baPWV tertile had a significantly high OR of poor outcome in comparison with patients with the lowest tertile. The proportion of patients with ABI \< 0.9 was slightly higher in this previous study (8.8%) than in our study (8.4%). Additionally, the proportion of patients with ABI \< 0.9 was lower in their lowest baPWV tertile (\< 1755 cm/s, 6.3%) than in our lower baPWV tertile (\< 1870 cm/s, 9.7%). Ishizuka K *et al.* also reported an association between baPWV and 3-month mRS in patients with acute stroke without consideration of ABI^[@bib9])^. Their study population was relatively small (*n* = 327), and the proportion of patients with mRS ≥ 3 was higher (32.1%) than that in our study (16.4%). Details about the proportion of patients with low ABI or PAD were not provided. Moreover, both of the previous reports included a stroke subtype of cardioembolic stroke. These differences might account for the inconsistent results between these previous studies and our study.

Our study indicates that the predictive power of baPWV is weaker than that of ABI for the outcome of non-cardioembolic stroke. There are several explanations for this result. First, baPWV was under estimated when patients had peripheral artery disease as mentioned above. Moreover, baPWV indicates arterial stiffness that increases because of atherosclerosis. On the other hand, ABI indicates stenosis or obstruction of the artery that in turn indicates a progressed stage of atherosclerosis. Therefore, ABI may indicate severe atherosclerosis that has an impact on stroke outcome more directly than baPWV.

Limitations
===========

There are several limitations in this study. First, this study was a single hospital retrospective study. This setting may have caused selection bias in our results. Second, there were significant differences in stroke severity at admission among the groups. In particular patients with ABI \< 0.9 had a high NIHSS score at admission. Although we included the NIHSS score for adjustment in the models of multivariate analysis, the difference may have influenced the prediction of stroke outcome with ABI and baPWV.

Conclusion
==========

Our study suggests that the stroke outcome can be predicted using ABI, and to an extent using baPWV when ABI ≥ 0.9 in patients with non-cardioembolic stroke. Further studies evaluating ABI or baPWV for their association with stroke outcome should be designed considering their inter-relationship.
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